Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER) Food and Drug Administration Dept. of Health and Human Services (HHS) Peter.Marks@fda.hhs.gov April 16, 2022   Dear Dr. Marks,  I’ve just read an article stating highly inflammatory lipid nanoparticles (LNP)s “could be responsible for adjuvanticity and some […]